Regeneron and Sanofi announced that the FDA has updated the Dupixent® (dupilumab) label to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement. The new data has also been added to the Dupixent label in the European Union, with regulatory submissions underway in additional countries. The data is from the first and only trial evaluating a biologic specifically for this difficult-to-treat population.
On 27 November 2023, Sanofi and Regeneron announced they plan to file a supplemental biologics licence application with the FDA for Dupixent® to treat chronic obstructive pulmonary disease (COPD) by the end of 2023.